Treatment With Tofacitinib in Refractory Psoriatic Arthritis: A National Multicenter Study of the First 87 Patients in Clinical Practice.
Por:
Galíndez-Agirregoikoa E, Prieto-Peña D, Martín-Varillas JL, Joven B, Rusinovich O, Melero-González RB, Ortiz-Sanjuan F, Almodóvar R, Alegre JJ, Martínez Á, Sellas-Fernández A, Méndez L, García-Vicuña R, Atienza-Mateo B, Gorostiza I, González-Gay MÁ and Blanco R
Publicada:
1 oct 2021
Ahead of Print:
1 abr 2021
Resumen:
OBJECTIVE: Tofacitinib (TOF) is the first Janus kinase (JAK) inhibitor approved for psoriatic arthritis (PsA). It has shown efficacy in patients refractory to anti-tumor necrosis factor-a in randomized controlled trials (RCTs). Our aim was to assess efficacy and safety of TOF in clinical practice. METHODS: This was an observational, open-label multicenter study of PsA patients treated with TOF due to inefficacy or adverse events of previous therapies. Outcome variables were efficacy, corticosteroid dose-sparing effect, retention rate, and safety. A comparative study of clinical features between our cohort of patients and those from the OPAL Beyond trial was performed. RESULTS: There were 87 patients (28 women/59 men), with a mean age of 52.8 ± 11.4 years. All patients were refractory to biologic disease-modifying antirheumatic drugs (DMARDs) and/or to conventional synthetic DMARDs plus apremilast. TOF was started at 5 mg twice daily after a mean follow-up of 12.3 ± 9.3 years from PsA diagnosis. At first month, Disease Activity Score in 28 joints based on erythrocyte sedimentation rate (DAS28-ESR) decreased from median 4.8 (IQR 4.1-5.4) to 3.7 (IQR 2.8-4.7, P < 0.01), Disease Activity Index for Psoriatic Arthritis from median 28 (IQR 18.4-34.1) to 15.5 (IQR 10.1-25.7, P < 0.01), and C-reactive protein from median 1.9 (IQR 0.3-5.0) to 0.5 (IQR 0.1-2.2) mg/dL (P < 0.01). Also, TOF led to a significant reduction in prednisone dose. Mild adverse effects were reported in 21 patients (24.13%), mainly gastrointestinal symptoms. TOF retention rate at Month 6 was 77% (95% CI 65.2-86.3). Patients in clinical practice were older with longer disease duration and received biologic agents more commonly than those in the OPAL Beyond trial. CONCLUSION: Data from clinical practice confirm that TOF seems to be effective, rapid, and relatively safe in refractory PsA despite clinical differences with patients in RCTs.
Filiaciones:
Galíndez-Agirregoikoa E:
Rheumatology Department, Hospital Universitario de Basurto, Bilbao, Spain
Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander, Spain
Rheumatology Department, Hospital de Sierrallana, Torrelavega, Spain
Rheumatology Department, Hospital Universitario 12 de octubre, Madrid, Spain
Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain
Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia, Spain
Rheumatology Department, Fundación Alcorcón, Madrid, Spain. Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain
Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Spain
Rheumatology Department, Hospital Virgen del Rocío, Sevilla, Spain
Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAMRoche (EPID-Future), Universidad Autónoma de Madrid, Madrid, Spain
Research Group, Hospital Universitario de Basurto, Bilbao, Spain. University of Cantabria, School of Medicine, Santander, Spain
personal fees from Biogen, Celltrion and Mylan
Prieto-Peña D:
Rheumatology Department, Hospital Universitario de Basurto, Bilbao, Spain
Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander, Spain
Rheumatology Department, Hospital de Sierrallana, Torrelavega, Spain
Rheumatology Department, Hospital Universitario 12 de octubre, Madrid, Spain
Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain
Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia, Spain
Rheumatology Department, Fundación Alcorcón, Madrid, Spain. Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain
Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Spain
Rheumatology Department, Hospital Virgen del Rocío, Sevilla, Spain
Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAMRoche (EPID-Future), Universidad Autónoma de Madrid, Madrid, Spain
Research Group, Hospital Universitario de Basurto, Bilbao, Spain. University of Cantabria, School of Medicine, Santander, Spain
personal fees from Biogen, Celltrion and Mylan
Martín-Varillas JL:
Rheumatology Department, Hospital Universitario de Basurto, Bilbao, Spain
Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander, Spain
Rheumatology Department, Hospital de Sierrallana, Torrelavega, Spain
Rheumatology Department, Hospital Universitario 12 de octubre, Madrid, Spain
Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain
Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia, Spain
Rheumatology Department, Fundación Alcorcón, Madrid, Spain. Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain
Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Spain
Rheumatology Department, Hospital Virgen del Rocío, Sevilla, Spain
Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAMRoche (EPID-Future), Universidad Autónoma de Madrid, Madrid, Spain
Research Group, Hospital Universitario de Basurto, Bilbao, Spain. University of Cantabria, School of Medicine, Santander, Spain
personal fees from Biogen, Celltrion and Mylan
Joven B:
Rheumatology Department, Hospital Universitario de Basurto, Bilbao, Spain
Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander, Spain
Rheumatology Department, Hospital de Sierrallana, Torrelavega, Spain
Rheumatology Department, Hospital Universitario 12 de octubre, Madrid, Spain
Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain
Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia, Spain
Rheumatology Department, Fundación Alcorcón, Madrid, Spain. Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain
Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Spain
Rheumatology Department, Hospital Virgen del Rocío, Sevilla, Spain
Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAMRoche (EPID-Future), Universidad Autónoma de Madrid, Madrid, Spain
Research Group, Hospital Universitario de Basurto, Bilbao, Spain. University of Cantabria, School of Medicine, Santander, Spain
personal fees from Biogen, Celltrion and Mylan
Rusinovich O:
Rheumatology Department, Hospital Universitario de Basurto, Bilbao, Spain
Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander, Spain
Rheumatology Department, Hospital de Sierrallana, Torrelavega, Spain
Rheumatology Department, Hospital Universitario 12 de octubre, Madrid, Spain
Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain
Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia, Spain
Rheumatology Department, Fundación Alcorcón, Madrid, Spain. Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain
Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Spain
Rheumatology Department, Hospital Virgen del Rocío, Sevilla, Spain
Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAMRoche (EPID-Future), Universidad Autónoma de Madrid, Madrid, Spain
Research Group, Hospital Universitario de Basurto, Bilbao, Spain. University of Cantabria, School of Medicine, Santander, Spain
personal fees from Biogen, Celltrion and Mylan
Melero-González RB:
Rheumatology Department, Hospital Universitario de Basurto, Bilbao, Spain
Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander, Spain
Rheumatology Department, Hospital de Sierrallana, Torrelavega, Spain
Rheumatology Department, Hospital Universitario 12 de octubre, Madrid, Spain
Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain
Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia, Spain
Rheumatology Department, Fundación Alcorcón, Madrid, Spain. Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain
Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Spain
Rheumatology Department, Hospital Virgen del Rocío, Sevilla, Spain
Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAMRoche (EPID-Future), Universidad Autónoma de Madrid, Madrid, Spain
Research Group, Hospital Universitario de Basurto, Bilbao, Spain. University of Cantabria, School of Medicine, Santander, Spain
personal fees from Biogen, Celltrion and Mylan
Ortiz-Sanjuan F:
Rheumatology Department, Hospital Universitario de Basurto, Bilbao, Spain
Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander, Spain
Rheumatology Department, Hospital de Sierrallana, Torrelavega, Spain
Rheumatology Department, Hospital Universitario 12 de octubre, Madrid, Spain
Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain
Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia, Spain
Rheumatology Department, Fundación Alcorcón, Madrid, Spain. Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain
Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Spain
Rheumatology Department, Hospital Virgen del Rocío, Sevilla, Spain
Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAMRoche (EPID-Future), Universidad Autónoma de Madrid, Madrid, Spain
Research Group, Hospital Universitario de Basurto, Bilbao, Spain. University of Cantabria, School of Medicine, Santander, Spain
personal fees from Biogen, Celltrion and Mylan
Almodóvar R:
Rheumatology Department, Hospital Universitario de Basurto, Bilbao, Spain
Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander, Spain
Rheumatology Department, Hospital de Sierrallana, Torrelavega, Spain
Rheumatology Department, Hospital Universitario 12 de octubre, Madrid, Spain
Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain
Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia, Spain
Rheumatology Department, Fundación Alcorcón, Madrid, Spain. Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain
Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Spain
Rheumatology Department, Hospital Virgen del Rocío, Sevilla, Spain
Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAMRoche (EPID-Future), Universidad Autónoma de Madrid, Madrid, Spain
Research Group, Hospital Universitario de Basurto, Bilbao, Spain. University of Cantabria, School of Medicine, Santander, Spain
personal fees from Biogen, Celltrion and Mylan
:
Rheumatology Department, Hospital Universitario de Basurto, Bilbao, Spain
Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander, Spain
Rheumatology Department, Hospital de Sierrallana, Torrelavega, Spain
Rheumatology Department, Hospital Universitario 12 de octubre, Madrid, Spain
Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain
Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia, Spain
Rheumatology Department, Fundación Alcorcón, Madrid, Spain. Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain
Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Spain
Rheumatology Department, Hospital Virgen del Rocío, Sevilla, Spain
Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAMRoche (EPID-Future), Universidad Autónoma de Madrid, Madrid, Spain
Research Group, Hospital Universitario de Basurto, Bilbao, Spain. University of Cantabria, School of Medicine, Santander, Spain
personal fees from Biogen, Celltrion and Mylan
Martínez Á:
Rheumatology Department, Hospital Universitario de Basurto, Bilbao, Spain
Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander, Spain
Rheumatology Department, Hospital de Sierrallana, Torrelavega, Spain
Rheumatology Department, Hospital Universitario 12 de octubre, Madrid, Spain
Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain
Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia, Spain
Rheumatology Department, Fundación Alcorcón, Madrid, Spain. Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain
Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Spain
Rheumatology Department, Hospital Virgen del Rocío, Sevilla, Spain
Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAMRoche (EPID-Future), Universidad Autónoma de Madrid, Madrid, Spain
Research Group, Hospital Universitario de Basurto, Bilbao, Spain. University of Cantabria, School of Medicine, Santander, Spain
personal fees from Biogen, Celltrion and Mylan
Sellas-Fernández A:
Rheumatology Department, Hospital Universitario de Basurto, Bilbao, Spain
Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander, Spain
Rheumatology Department, Hospital de Sierrallana, Torrelavega, Spain
Rheumatology Department, Hospital Universitario 12 de octubre, Madrid, Spain
Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain
Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia, Spain
Rheumatology Department, Fundación Alcorcón, Madrid, Spain. Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain
Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Spain
Rheumatology Department, Hospital Virgen del Rocío, Sevilla, Spain
Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAMRoche (EPID-Future), Universidad Autónoma de Madrid, Madrid, Spain
Research Group, Hospital Universitario de Basurto, Bilbao, Spain. University of Cantabria, School of Medicine, Santander, Spain
personal fees from Biogen, Celltrion and Mylan
Méndez L:
Rheumatology Department, Hospital Universitario de Basurto, Bilbao, Spain
Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander, Spain
Rheumatology Department, Hospital de Sierrallana, Torrelavega, Spain
Rheumatology Department, Hospital Universitario 12 de octubre, Madrid, Spain
Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain
Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia, Spain
Rheumatology Department, Fundación Alcorcón, Madrid, Spain. Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain
Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Spain
Rheumatology Department, Hospital Virgen del Rocío, Sevilla, Spain
Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAMRoche (EPID-Future), Universidad Autónoma de Madrid, Madrid, Spain
Research Group, Hospital Universitario de Basurto, Bilbao, Spain. University of Cantabria, School of Medicine, Santander, Spain
personal fees from Biogen, Celltrion and Mylan
García-Vicuña R:
Rheumatology Department, Hospital Universitario de Basurto, Bilbao, Spain
Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander, Spain
Rheumatology Department, Hospital de Sierrallana, Torrelavega, Spain
Rheumatology Department, Hospital Universitario 12 de octubre, Madrid, Spain
Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain
Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia, Spain
Rheumatology Department, Fundación Alcorcón, Madrid, Spain. Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain
Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Spain
Rheumatology Department, Hospital Virgen del Rocío, Sevilla, Spain
Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAMRoche (EPID-Future), Universidad Autónoma de Madrid, Madrid, Spain
Research Group, Hospital Universitario de Basurto, Bilbao, Spain. University of Cantabria, School of Medicine, Santander, Spain
personal fees from Biogen, Celltrion and Mylan
Atienza-Mateo B:
Rheumatology Department, Hospital Universitario de Basurto, Bilbao, Spain
Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander, Spain
Rheumatology Department, Hospital de Sierrallana, Torrelavega, Spain
Rheumatology Department, Hospital Universitario 12 de octubre, Madrid, Spain
Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain
Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia, Spain
Rheumatology Department, Fundación Alcorcón, Madrid, Spain. Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain
Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Spain
Rheumatology Department, Hospital Virgen del Rocío, Sevilla, Spain
Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAMRoche (EPID-Future), Universidad Autónoma de Madrid, Madrid, Spain
Research Group, Hospital Universitario de Basurto, Bilbao, Spain. University of Cantabria, School of Medicine, Santander, Spain
personal fees from Biogen, Celltrion and Mylan
Gorostiza I:
Rheumatology Department, Hospital Universitario de Basurto, Bilbao, Spain
Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander, Spain
Rheumatology Department, Hospital de Sierrallana, Torrelavega, Spain
Rheumatology Department, Hospital Universitario 12 de octubre, Madrid, Spain
Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain
Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia, Spain
Rheumatology Department, Fundación Alcorcón, Madrid, Spain. Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain
Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Spain
Rheumatology Department, Hospital Virgen del Rocío, Sevilla, Spain
Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAMRoche (EPID-Future), Universidad Autónoma de Madrid, Madrid, Spain
Research Group, Hospital Universitario de Basurto, Bilbao, Spain. University of Cantabria, School of Medicine, Santander, Spain
personal fees from Biogen, Celltrion and Mylan
González-Gay MÁ:
Rheumatology Department, Hospital Universitario de Basurto, Bilbao, Spain
Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander, Spain
Rheumatology Department, Hospital de Sierrallana, Torrelavega, Spain
Rheumatology Department, Hospital Universitario 12 de octubre, Madrid, Spain
Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain
Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia, Spain
Rheumatology Department, Fundación Alcorcón, Madrid, Spain. Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain
Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Spain
Rheumatology Department, Hospital Virgen del Rocío, Sevilla, Spain
Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAMRoche (EPID-Future), Universidad Autónoma de Madrid, Madrid, Spain
Research Group, Hospital Universitario de Basurto, Bilbao, Spain. University of Cantabria, School of Medicine, Santander, Spain
personal fees from Biogen, Celltrion and Mylan
Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. This study was presented in part at the European e-Congress of Rheumatology 2020 (EULAR 2020). Disclosures that might be interpreted as constituting of possible conflict(s) of interest for the study: Dra. Galíndez-Agirregoikoa has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, Bristol-Myers, Janss
grants from Roche, grants, personal fees and non-financial support from Sanofi, grants, personal fees and non-financial support from Sandoz, grants and personal fees from Janssen, outside the submitted work. Dr. Atienza-Mateo is a recipient of a 'López-Albo' Post- Residency Programme funded by Servicio Cantabro de Salud and she received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene and GSK.Dr. MA Gonzalez-Gay received grants/research supports from Abbott, MSD and Roche
|